AUS
NZ
UK
CA
USA
IND
A major player of Healthcare sector, GSK PLC (NYSE:GSK) has received Breakthrough Therapy Designation (BTD) in China for its blood cancer medication, Blenrep (belantamab mafodotin). The designation, granted by the National Medical Products Administration (NMPA), is intended to expedite the development of treatments that offer significant improvements over existing options for serious diseases.
Breakthrough Therapy Designation and Trial Results
The BTD was awarded based on promising interim results from the phase III DREAMM-7 trial. The trial demonstrated notable advancements in progression-free survival for patients with relapsed or refractory multiple myeloma, a type of blood cancer. Blenrep, when combined with two existing treatments, showed improvements compared to current standard therapies.
While overall survival results are still under review, the trial data indicated that Blenrep in conjunction with a regimen known as BorDex provided deeper and more durable responses. The combination therapy’s performance is expected to offer new treatment avenues for multiple myeloma patients, who face challenging prognoses with existing therapies.
Growing Need for Effective Treatments
Multiple myeloma presents a significant health issue in China, with approximately 30,000 new cases reported annually. Over the past three decades, the incidence and mortality rates associated with this disease have risen sharply. The accelerated development of effective treatments such as Blenrep could address the increasing demand for improved therapeutic options.
Future Outlook
The Breakthrough Therapy Designation will facilitate a faster review and approval process for Blenrep in China, aiming to bring this promising treatment to patients sooner. GSK (NYSE:GSK)’s ongoing efforts in this area reflect the company’s commitment to addressing urgent medical needs in oncology.
